At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,210 enrolled
Drug / intervention
Earlytect Colon Cancerother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test
In Brief
A clinical study evaluating Earlytect Colon Cancer for Colorectal Cancer and 2 related conditions. Completed, enrolled 1,210 participants across 8 sites.
Detailed Summary
A study of colorectal cancer screening using stool DNA-based SDC2 methylation test
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Colon Polyp, Healthy
CountriesSouth Korea
CollaboratorsGenomictree, Inc.
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartJun 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedMar 11, 2020
Enrollment StartJun 7, 2020
Primary CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.3 years ago
Interventions
Earlytect Colon Cancerother
A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer